Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 8/20 | 0.55 |
| ▸ | PGK2 | P07205 | 8/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PTPRB | P23467 | 2/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ACP3 | P15309 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617420 | 0.87 | PGK1 (0.67) | PGK1PGK2ENPP2PTPRBDGAT2 | |
| SCHEMBL27635376 | 0.82 | ENPP2 (0.56) | PGK1PGK2ENPP2PTPRBDGAT2 | |
| SCHEMBL1823591 | 0.81 | PGK1 (0.55) | PGK1PGK2ENPP2PTPRB | |
| SCHEMBL22973707 | 0.81 | PGK1 (0.61) | PGK1PGK2PTPRBACP3 | |
| SCHEMBL9407120 | 0.80 | PGK1 (0.59) | PGK1PGK2ENPP2PTPRBACP3 | |
| SCHEMBL11043660 | 0.79 | PGK1 (0.53) | PGK1PGK2ENPP2PTPRB | |
| SCHEMBL3361713 | 0.79 | PGK1 (0.56) | PGK1PGK2PTPRBACP3 | |
| SCHEMBL28212706 | 0.78 | PGK1 (0.61) | PGK1PGK2ENPP2PTPRBDGAT2 | |
| SCHEMBL915744 | 0.78 | PGK1 (0.57) | PGK1PGK2ENPP2PTPRB | |
| SCHEMBL22973715 | 0.77 | GRIN2D (0.47) | ENPP2CES2CES1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242631-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-12-21 | — | — | WO | disclosed |
| CN-110317230-B | Phosphate derivatives and use thereof | 上海昇悦医药科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11053267-B2 | Electrochromic compound, electrochromic composition, and display element | RICOH COMPANY, LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| US-10988684-B2 | Electrochromic compound, electrochromic composition, electrochromic element, and electrochromic dimming element | RICOH COMPANY, LTD. (JP) | 2021-04-27 | — | — | US | disclosed |
| EP-3778612-A1 | PHOSPHATE DERIVATIVES AND USE THEREOF | Zhu, Qing (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20200216478-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, AND DISPLAY ELEMENT | SAGISAKA TOSHIYA (JP) | 2020-07-09 | — | — | US | disclosed |
| EP-3268448-B1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, ELECTROCHROMIC ELEMENT, AND ELECTROCHROMIC DIMMING ELEMENT | RICOH CO LTD (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-10626133-B2 | Electrochromic compound, electrochromic composition, and display element | RICOH COMPANY, LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| CN-110317230-A | Phosphoric acid salt derivative and application thereof | 朱青 | 2019-10-11 | — | — | CN | disclosed |
| US-20190031694-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, AND DISPLAY ELEMENT | SAGISAKA TOSHIYA (JP) | 2019-01-31 | — | — | US | disclosed |
| WO-2005064008-A9 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2006-09-28 | — | — | WO | disclosed |
| CN-1780630-A | Phosphonate compounds having immunomodulatory activity | GILEAD SCIENCES INC (US) | 2006-05-31 | — | — | CN | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1115729-B1 | PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PTP-1B | MERCK FROSST CANADA INC (CA) | 2003-02-19 | — | — | EP | disclosed |
| US-6174874-B1 | ANTIDIABETIC,-CARCINOGENIC AGENTS; IMPROVING GLUCOSE TOLERANCE/INSULIN-SENSITIVITY; PREVENTING/TREATING OBESITY AND NEURODEGENERATIVE DISEASES; E.G. 1,3-BIS-((PHOSPHONODI-FLUOROMETHYL)PHENYL)-2-DICARBOXYPROPANE | MERCK FROSST CANADA & CO. (CA) | 2001-01-16 | — | — | US | disclosed |
| EP-0421436-A2 | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity | WARNER-LAMBERT COMPANY (US) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031694-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, AND DISPLAY ELEMENT | ANTXR2, SCN11A, H1-4 | PGK1 4198/4885PGK2 3420/4885ENPP2 382/4885 |
| US-10626133-B2 | Electrochromic compound, electrochromic composition, and display element | ANTXR2, SCN11A, H1-4 | PGK1 4198/4885PGK2 3420/4885ENPP2 382/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | PGK1 36/4885PGK2 148/4885ENPP2 1130/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | PGK1 172/4885PGK2 577/4885ENPP2 1093/4885 |
| US-20200216478-A1 | ELECTROCHROMIC COMPOUND, ELECTROCHROMIC COMPOSITION, AND DISPLAY ELEMENT | SCN11A, H1-10, H1-2 | PGK1 4229/4885PGK2 3471/4885ENPP2 447/4885 |
| US-11053267-B2 | Electrochromic compound, electrochromic composition, and display element | SCN11A, H1-10, H1-2 | PGK1 4229/4885PGK2 3471/4885ENPP2 447/4885 |
| US-10988684-B2 | Electrochromic compound, electrochromic composition, electrochromic element, and electrochromic dimming element | ETV6, AP2M1, KCNH3 | PGK1 1704/4885PGK2 1382/4885ENPP2 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.